CBL-514 clinical trials
Also written CBL-514.
How each study uses CBL-514 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CBL-514 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2026 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test CBL-514, phase 3 first.
- Jul 2027A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous FatPhase 3 · Caliway Biopharmaceuticals Co., Ltd.
- Aug 2027A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )Phase 3 · Caliway Biopharmaceuticals Co., Ltd.
- Apr 2027A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatPhase 2 · Caliway Biopharmaceuticals Co., Ltd.
Studies
Open first, then newest update. How each study uses CBL-514 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )Not yet recruitingPhase 3Caliway Biopharmaceuticals Co., Ltd.NCT07526974Written as CBL-514 Injection
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatNot yet recruitingPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT07608757Written as CBL-514 Injection
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatRecruitingPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT07608770Written as CBL-514 Injection
- A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)Not yet recruitingPhase 3Caliway Biopharmaceuticals Co., Ltd.NCT07733947Written as CBL-514 Injection
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous FatRecruitingPhase 3Caliway Biopharmaceuticals Co., Ltd.NCT07140939Written as CBL-514 Injection
- A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease LipomasCompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT06303570Written as CBL-514 injection
- A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)CompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT05836779Written as CBL-514 injection
- A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy VolunteersCompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT05234736Written as CBL-514
- A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.CompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT06005441Written as CBL-514 injection
- A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)CompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT04575467Written as CBL-514
- A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatCompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT05736107Written as CBL-514 Injection
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)CompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT04897412Written as CBL-514 Injection
- A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous FatCompletedPhase 2Caliway Biopharmaceuticals Co., Ltd.NCT04698642Written as CBL-514
- A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy VolunteersCompletedPhase 1Caliway Biopharmaceuticals Co., Ltd.NCT04699669Written as CBL-514